Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.